Intuitive Ventures

Capstan Medical specializes in developing minimally invasive technologies for treating heart valve disorders. Their core product is a catheter-based system designed to revolutionize the treatment of structural heart disease, providing a less invasive alternative to traditional open heart surgery. This technology ensures precise and reliable placement of heart valve implants, reducing recovery time and minimizing the risk of complications for patients.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Capstan Medical specializes in developing minimally invasive technologies for treating heart valve disorders. Their core product is a catheter-based system designed to revolutionize the treatment of structural heart disease, providing a less invasive alternative to traditional open heart surgery. This technology ensures precise and reliable placement of heart valve implants, reducing recovery time and minimizing the risk of complications for patients.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

Dasera, Inc. is a data security company based in Sunnyvale, California, that specializes in Data Security Posture Management (DSPM). Founded in 2019, Dasera has developed a query analysis engine designed to enhance data security by automatically identifying, flagging, and rewriting unsafe queries within data warehouses. This innovative platform not only prevents data breaches by monitoring query behavior but also helps organizations manage risks associated with their data lifecycle, from creation to deletion. By automating security and governance controls across structured and unstructured data in various environments, Dasera aims to ensure compliance with evolving data privacy regulations while fostering trust between consumers and companies through the safe use of sensitive data.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.

SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.

Optellum Ltd is a UK-based company founded in 2015 that specializes in artificial intelligence clinical decision support software specifically for lung cancer diagnosis and treatment. The company has developed an imaging biomarker aimed at enhancing the early detection of lung cancer, the most prevalent and deadly form of cancer globally. Optellum's innovative platform leverages machine learning to analyze vast patient datasets, enabling personalized diagnosis and therapy management for patients at high risk of developing lung cancer. The software not only identifies at-risk patients but also facilitates optimal therapy by automating the analysis of radiology reports, thereby improving clinical decision-making. The founding team consists of experts in medical imaging software and AI, with experience in successfully bringing innovations to market. Optellum is supported by a distinguished Advisory Board of clinicians and deep learning specialists, and is actively expanding its product development team to further its mission in cancer care.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

KelaHealth, Inc. is a healthcare technology company that specializes in developing clinical decision support software focused on surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering tailored recommendations to mitigate these issues. By analyzing patient data, the platform enhances the quality of surgical care and improves clinical operations. It aims to standardize practices among surgeons by suggesting patient-specific interventions, thereby addressing both clinical and administrative needs for quality compliance. KelaHealth is committed to creating a learning ecosystem that continuously enhances surgical outcomes through improved risk assessment and tracking of long-term patient results.

KelaHealth, Inc. is a healthcare technology company that specializes in developing clinical decision support software focused on surgical care. Founded in 2016 and based in San Francisco, California, KelaHealth's platform utilizes predictive analytics to identify potential surgical complications and risks, offering tailored recommendations to mitigate these issues. By analyzing patient data, the platform enhances the quality of surgical care and improves clinical operations. It aims to standardize practices among surgeons by suggesting patient-specific interventions, thereby addressing both clinical and administrative needs for quality compliance. KelaHealth is committed to creating a learning ecosystem that continuously enhances surgical outcomes through improved risk assessment and tracking of long-term patient results.